课题基金 / 基金详情

Developmental Basis of Aneurysm in Marfan Syndrome and Therapeutic Implication

Developmental Basis of Aneurysm in Marfan Syndrome and Therapeutic Implication
马凡氏综合征动脉瘤的发生基础及治疗意义
批准号:
8527710
负责人:
Francesco B Ramirez
金额:
$26.74万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2015-08-31
关键词:
AGTR2 geneAbnormal CellAdultAgonistAllelesAneurysmAngiotensin IIAngiotensinsAnimal ModelAortaAortic AneurysmAttenuatedAutomobile DrivingBMP7 geneBehaviorBiological AvailabilityBlood VesselsCardiacCellsCessation of lifeClinicalClinical TrialsCollaborationsComplementComplexDataDeveloped CountriesDevelopmentDiseaseDisease ProgressionDissectionEndothelial CellsEnvironmentEnzymesEventExhibitsFBN1FDA approvedFamilyFibrosisFutureGenerationsGenesGeneticGenetic Predisposition to DiseaseGenotypeGrowth FactorHeartHomeostasisIndividualIntegrinsInterventionKnowledgeLeadLifeLigandsLightLosartanLungMAP2K1 geneMAPK14 geneMAPK3 geneMarfan SyndromeMatrix MetalloproteinasesMedialMediatingMediator of activation proteinMesenchymalModelingMusMuscleMutationMyofibroblastMyopathyNeonatalNeural CrestNormal CellPECAM1 genePathogenesisPathologicPathway interactionsPerformancePhenotypePhosphorylationProcessProductionPropertyProteinsPulmonary EmphysemaRecombinantsRelative (related person)ReporterSamplingSeriesSeveritiesSignal TransductionSkeletal MuscleSkeletonSmooth Muscle Actin Staining MethodSorting - Cell MovementStratificationSurveysSystemTGFB1 geneTestingTherapeuticTherapeutic AgentsTherapeutic EffectThinkingThrombospondin 1TimeTissuesTransforming Growth Factor betaTranslational ResearchTranslationsType 2 Angiotensin II ReceptorU-0126Up-RegulationVascular DiseasesWorkascending aortaautocrinebaseextracellularfasudilhuman diseaseinhibitor/antagonistinsightmeetingsmouse modelmutantneutralizing antibodynovelnovel therapeuticsoptimismparacrinepostnatalpreventprotective effectreceptorresponserho GTP-Binding Proteinstherapeutic target

项目摘要

项目成果

Francesco B Ramirez的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Marfan syndrome (MFS) is a common disorder caused by mutations in the gene encoding the matrix protein fibrillin-1. Our prior work has shown that many manifestations of MFS, including aortic aneurysm, valve disease, emphysema and skeletal muscle myopathy, are caused by excessive activation of and signaling by the TGF beta family of growth factors and can be attenuated by TGFbeta blockade in mouse models. The prevailing view has been that MFS manifests abnormal behaviors of "normal" cells due to alterations in their extracellular environment. We now present evidence for "abnormal" cells within the aortic wall of adult MFS mice that have undergone a TGFbeta-dependent permanent transition in identity and character during early development due to a process termed endothelial-to-mesenchymal transition (EnMT). After transition, resulting myofibroblasts exhibit many deleterious behaviors including high TGFbeta signaling, angiotensin II (Angll)-dependent fibrosis, and high expression of matrix-degrading enzymes. The major hypotheses to be tested in this work are that EnMT-derived cells drive progression of disease and that EnMT continues to populate the ascending aorta during postnatal life in disease states. Using mouse models, we will determine the pathways that drive EnMT in the aorta of fibrillin-1 deficient mice and will purify EnMT-derived cells, allowing identification of their deleterious behaviors and exploration of strategies to tame them. Currently, we can envision at least 9 different therapeutic agents that will theoretically prevent ongoing EnMT and/or modulate the nonproductive performance of myofibroblasts resident within the aortic wall at the time of initiation of treatment. These will be tested in genetically defined and validated mouse models of MFS. Remarkably, a number of these agents are already in clinical use for other indications, suggesting the potential for rapid translation to people with MFS. Our current data suggest a developmentally-imposed fixed alteration in cellular identify in the prediposition for apparently acquired late-onset phenotypes in MFS, This paradigm represents a novel way of thinking about genetic predisposition, aids in the elucidation of therapeutic limitations and opportunities, and will likely prove relevant to other conditions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of Altered Mechanosensing in Mouse Models of ECM-induced TAA
Tendon-dependent Control of Longitudinal Bone Growth
Structural microenvironment of bone marrow stem cells
Consortium for Translational Research in Marfan Syndrome
海外基金